Primary Immunodeficiency and Cancer in Children; A Review of the Literature

Author(s): Rejin Kebudi*, Ayca Kiykim, Merve K. Sahin

Journal Name: Current Pediatric Reviews

Volume 15 , Issue 4 , 2019


Become EABM
Become Reviewer
Call for Editor

Abstract:

The life span of patients with primary and secondary immunodeficiencies has increased due to recent advances in diagnostic and therapeutic strategies. Primary immune deficiencies (PIDs) are genetic disorders that predispose patients to frequent infections, autoimmunity and malignancies. Genomic instability due to defective DNA repair processes and other unknown mechanisms in patients with PID leads to an enhanced risk of cancer. PIDs were originally described as rare diseases occurring only in infants and young children, which are associated with severe clinical symptoms. However, advances in gene sequencing technologies, have revealed that they are much more common than originally appreciated and are present in older children, adolescents, and adults. After infection, malignancy is the most prevalent cause of death in both children and adults with PIDs. The overall risk of developing cancer in patients with PID is estimated to range from 4.7 to 5.7 percent. A 1.4 to 1.6-fold excess relative risk of cancer has been reported for PIDs. Increasing awareness among physicians regarding PID and cancer may lead to earlier diagnosis which may decrease morbidity and mortality. In this paper, we review the various categories of PIDs in children and highlight their association with various malignancies. MEDLINE was searched to identify articles for inclusion. Three authors have independently screened literature search results from MEDLINE and abstracted data from studies dealing with cancers of children among primary immune deficiencies.

Keywords: Malignancy, primary immune deficiency, children, lymphoma, genomic, tumor.

[1]
Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
[PMID: 4921480]
[2]
Burnet M. Cancer: A biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. BMJ 1957; 1(5023): 841-7.
[http://dx.doi.org/10.1136/bmj.1.5023.841] [PMID: 13413231]
[3]
Thomas L. Discussion Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper 1959; pp. 529-32.
[4]
Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55(3-4): 329-33.
[PMID: 6758376]
[5]
Corthay A. Does the immune system naturally protect against cancer? Front Immunol 2014; 5: 197.
[http://dx.doi.org/10.3389/fimmu.2014.00197] [PMID: 24860567]
[6]
Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Allergy Clin Immunol 2018; 141(1): 59-68.
[http://dx.doi.org/10.1016/j.jaci.2017.06.009] [PMID: 28669558]
[7]
Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010; 116(8): 1228-34.
[http://dx.doi.org/10.1182/blood-2010-03-272351] [PMID: 20466855]
[8]
Quiding-Järbrink M, Sundström P, Lundgren A, et al. Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. Clin Immunol 2009; 131(3): 463-71.
[http://dx.doi.org/10.1016/j.clim.2009.01.010] [PMID: 19249247]
[9]
Zhang RG, Duan GC, Fan QT, Chen SY. Role of Helicobacter pylori infection in pathogenesis of gastric carcinoma. World J Gastrointest Pathophysiol 2016; 7(1): 97-107.
[http://dx.doi.org/10.4291/wjgp.v7.i1.97] [PMID: 26909232]
[10]
Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 2018; 141(3): 1028-35.
[http://dx.doi.org/10.1016/j.jaci.2017.05.024] [PMID: 28606585]
[11]
Jonkman-Berk BM, van den Berg JM, Ten Berge IJ, et al. Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy. Clin Immunol 2015; 156(2): 154-62.
[http://dx.doi.org/10.1016/j.clim.2014.10.003] [PMID: 25451158]
[12]
Tanyildiz HG, Dincaslan H, Yavuz G, et al. Lymphoma secondary to congenital and acquired immunodeficiency syndromes at a Turkish pediatric oncology center. J Clin Immunol 2016; 36(7): 667-76.
[http://dx.doi.org/10.1007/s10875-016-0324-z] [PMID: 27492260]
[13]
Seidemann K, Tiemann M, Henze G, Sauerbrey A, Müller S, Reiter A. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999; 33(6): 536-44.
[http://dx.doi.org/10.1002/(SICI)1096-911X(199912)33:6<536:AID-MPO3>3.0.CO;2-Z] [PMID: 10573576]
[14]
Seidemann K, Henze G, Beck JD, et al. Non-Hodgkin’s lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol 2000; 11(Suppl. 1): 141-5.
[http://dx.doi.org/10.1093/annonc/11.suppl_1.S141] [PMID: 10707797]
[15]
Shabani M, Nichols KE, Rezaei N. Primary immunodeficiencies associated with EBV-Induced lymphoproliferative disorders. Crit Rev Oncol Hematol 2016; 108: 109-27.
[http://dx.doi.org/10.1016/j.critrevonc.2016.10.014] [PMID: 27931829]
[16]
Parvaneh N, Filipovich AH, Borkhardt A. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. Br J Haematol 2013; 162(5): 573-86.
[http://dx.doi.org/10.1111/bjh.12422] [PMID: 23758097]
[17]
Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: An update on the classification from the International union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol 2015; 35(8): 696-726.
[http://dx.doi.org/10.1007/s10875-015-0201-1] [PMID: 26482257]
[18]
Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol 2018; 38(1): 129-43.
[http://dx.doi.org/10.1007/s10875-017-0465-8] [PMID: 29226301]
[19]
Cipe FE, Aydogmus C, Serwas NK, et al. ITK deficiency: how can EBV be treated before lymphoma? Pediatr Blood Cancer 2015; 62(12): 2247-8.
[http://dx.doi.org/10.1002/pbc.25648] [PMID: 26174447]
[20]
Alme C, Satwani P, Alobeid B, Bhagat G, Kelly KM. Atypical clinical course in pediatric hodgkin lymphoma: association with germline mutations in interleukin-2-inducible t-cell kinase. J Pediatr Hematol Oncol 2015; 37(7): 507-8.
[http://dx.doi.org/10.1097/MPH.0000000000000366] [PMID: 26056787]
[21]
Stepensky P, Weintraub M, Yanir A, et al. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 2011; 96(3): 472-6.
[http://dx.doi.org/10.3324/haematol.2010.033910] [PMID: 21109689]
[22]
Rezaei N, Mahmoudi E, Aghamohammadi A, Das R, Nichols KE. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 2011; 152(1): 13-30.
[http://dx.doi.org/10.1111/j.1365-2141.2010.08442.x] [PMID: 21083659]
[23]
Sumazaki R, Kanegane H, Osaki M, et al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus--associated illnesses. Blood 2001; 98(4): 1268-70.
[http://dx.doi.org/10.1182/blood.V98.4.1268] [PMID: 11493483]
[24]
Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transplant 2014; 20(10): 1641-5.
[http://dx.doi.org/10.1016/j.bbmt.2014.06.003] [PMID: 24923536]
[25]
Somekh I, Marquardt B, Liu Y, et al. Novel mutations in RASGRP1 are associated with immunodeficiency, immune dysregulation, and EBV-induced lymphoma. J Clin Immunol 2018; 38(6): 699-710.
[http://dx.doi.org/10.1007/s10875-018-0533-8] [PMID: 30030704]
[26]
Alkhairy OK, Perez-Becker R, Driessen GJ, et al. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency. J Allergy Clin Immunol 2015; 136(3): 703-12. e10
[http://dx.doi.org/10.1016/j.jaci.2015.02.022] [PMID: 25843314]
[27]
Abolhassani H, Edwards ES, Ikinciogullari A, et al. Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med 2017; 214(1): 91-106.
[http://dx.doi.org/10.1084/jem.20160849] [PMID: 28011864]
[28]
Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol 2015; 33(2): 202-8.
[http://dx.doi.org/10.1200/JCO.2014.56.5101] [PMID: 25488969]
[29]
Wolska-Kuśnierz B, Gregorek H, Chrzanowska K, et al. Inborn errors working party of the society for European blood and marrow transplantation and the European society for immune deficiencies. Nijmegen breakage syndrome: Clinical and immunological features, long-term outcome and treatment options - A Retrospective Analysis. J Clin Immunol 2015; 35(6): 538-49.
[http://dx.doi.org/10.1007/s10875-015-0186-9] [PMID: 26271390]
[30]
Chrzanowska KH, Gregorek H, Dembowska-Bagińska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012; 7: 13.
[http://dx.doi.org/10.1186/1750-1172-7-13] [PMID: 22373003]
[31]
Toita N, Hatano N, Ono S, et al. Epstein-Barr virus-associated B-cell lymphoma in a patient with DNA ligase IV (LIG4) syndrome. Am J Med Genet A 2007; 143A(7): 742-5.
[http://dx.doi.org/10.1002/ajmg.a.31644] [PMID: 17345618]
[32]
Buck D, Moshous D, de Chasseval R, et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 2006; 36(1): 224-35.
[http://dx.doi.org/10.1002/eji.200535401] [PMID: 16358361]
[33]
Ben-Omran TI, Cerosaletti K, Concannon P, Weitzman S, Nezarati MM. A patient with mutations in DNA Ligase IV: clinical features and overlap with Nijmegen breakage syndrome Am J Med Genet A 2005; 137A(3): 283-7.
[http://dx.doi.org/10.1002/ajmg.a.30869]
[34]
German J. Bloom’s syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997; 93(1): 100-6.
[http://dx.doi.org/10.1016/S0165-4608(96)00336-6] [PMID: 9062585]
[35]
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125(6 Pt 1): 876-85.
[http://dx.doi.org/10.1016/S0022-3476(05)82002-5] [PMID: 7996359]
[36]
Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103(2): 456-64.
[http://dx.doi.org/10.1182/blood-2003-05-1480] [PMID: 12969986]
[37]
Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22(5): 261-81.
[http://dx.doi.org/10.1016/j.blre.2008.03.009] [PMID: 18456377]
[38]
Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 2008; 28(2B): 1263-9.
[PMID: 18505064]
[39]
Du S, Scuderi R, Malicki DM, Willert J, Bastian J, Weidner N. Hodgkin’s and non-Hodgkin’s lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature. Pediatr Dev Pathol 2011; 14(1): 64-70.
[http://dx.doi.org/10.2350/10-01-0787-CR.1] [PMID: 20429642]
[40]
Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992; 52(19)(Suppl.): 5465s-7s.
[PMID: 1327508]
[41]
Moulding DA, Moeendarbary E, Valon L, Record J, Charras GT, Thrasher AJ. Excess F-actin mechanically impedes mitosis leading to cytokinesis failure in X-linked neutropenia by exceeding Aurora B kinase error correction capacity. Blood 2012; 120(18): 3803-11.
[http://dx.doi.org/10.1182/blood-2012-03-419663] [PMID: 22972986]
[42]
Morsheimer M, Brown Whitehorn TF, Heimall J, Sullivan KE. The immune deficiency of chromosome 22q11.2 deletion syndrome. Am J Med Genet A 2017; 173(9): 2366-72.
[http://dx.doi.org/10.1002/ajmg.a.38319] [PMID: 28627729]
[43]
McDonald-McGinn DM, Reilly A, Wallgren-Pettersson C, et al. Malignancy in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Am J Med Genet A 2006; 140(8): 906-9.
[http://dx.doi.org/10.1002/ajmg.a.31199] [PMID: 16532473]
[44]
Itoh S, Ohno T, Kakizaki S, Ichinohasama R. Epstein-Barr virus-positive T-cell lymphoma cells having chromosome 22q11.2 deletion: an autopsy report of DiGeorge syndrome. Hum Pathol 2011; 42(12): 2037-41.
[http://dx.doi.org/10.1016/j.humpath.2010.03.014] [PMID: 21683977]
[45]
Pongpruttipan T, Cook JR, Reyes-Mugica M, Spahr JE, Swerdlow SH. Pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue associated with granulomatous inflammation in a child with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome). J Pediatr 2012; 161(5): 954-8.
[http://dx.doi.org/10.1016/j.jpeds.2012.07.003] [PMID: 22920507]
[46]
Beddow RA, Smith M, Kidd A, Corbett R, Hunter AG. Diagnosis of distal 22q11.2 deletion syndrome in a patient with a teratoid/rhabdoid tumour. Eur J Med Genet 2011; 54(3): 295-8.
[http://dx.doi.org/10.1016/j.ejmg.2010.12.007] [PMID: 21187175]
[47]
Ramos JT, López-Laso E, Ruiz-Contreras J, Giancaspro E, Madero S. B cell non-Hodgkin’s lymphoma in a girl with the DiGeorge anomaly. Arch Dis Child 1999; 81(5): 444-5.
[http://dx.doi.org/10.1136/adc.81.5.444] [PMID: 10519724]
[48]
Kim KY, Hur JA, Kim KH, Cha YJ, Lee MJ, Kim DS. DiGeorge syndrome who developed lymphoproliferative mediastinal mass. Korean J Pediatr 2015; 58(3): 108-11.
[http://dx.doi.org/10.3345/kjp.2015.58.3.108] [PMID: 25861334]
[49]
Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002; 130(3): 495-500.
[http://dx.doi.org/10.1046/j.1365-2249.2002.02004.x] [PMID: 12452841]
[50]
Tak Manesh A, Azizi G, Heydari A, et al. Epidemiology and pathophysiology of malignancy in common variable immunodeficiency? Allergol Immunopathol (Madr) 2017; 45(6): 602-15.
[http://dx.doi.org/10.1016/j.aller.2017.01.006] [PMID: 28411962]
[51]
Rosenberg PS, Alter BP, Bolyard AA, et al. Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107(12): 4628-35.
[http://dx.doi.org/10.1182/blood-2005-11-4370] [PMID: 16497969]
[52]
Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 2007; 109(1): 93-9.
[http://dx.doi.org/10.1182/blood-2006-02-004275] [PMID: 16985178]
[53]
Shimamura A. Shwachman-Diamond syndrome. Semin Hematol 2006; 43(3): 178-88.
[http://dx.doi.org/10.1053/j.seminhematol.2006.04.006] [PMID: 16822460]
[54]
Wolach B, Ash S, Gavrieli R, Stark B, Yaniv I, Roos D. Acute lymphoblastic leukemia in a patient with chronic granulomatous disease and a novel mutation in CYBB: first report. Am J Hematol 2005; 80(1): 50-4.
[http://dx.doi.org/10.1002/ajh.20424] [PMID: 16138344]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 4
Year: 2019
Published on: 30 December, 2019
Page: [245 - 250]
Pages: 6
DOI: 10.2174/1573396315666190917154058

Article Metrics

PDF: 47
HTML: 9
EPUB: 1
PRC: 1